Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials
BMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j4461 (Published 25 September 2017) Cite this as: BMJ 2017;358:j4461
During the editing process of this Research paper (BMJ 2017;358:j3927, doi:10.1136/bmj.j3927) the word ‘not’ was omitted from the following sentence in the Discussion (third paragraph): “However, the higher relapse rate in the placebo group is probably attributable to withdrawal symptoms—that is, most of the studies tapered antidepressants thereby diminishing withdrawal symptoms.” This sentence should read: “However, the higher relapse rate in the placebo group is probably not attributable to withdrawal symptoms—that is, most of the studies tapered antidepressants thereby diminishing withdrawal symptoms.” This has now been corrected.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.